MX336145B - Metodo para el tratamiento de insuficiencia cardiaca cronica. - Google Patents

Metodo para el tratamiento de insuficiencia cardiaca cronica.

Info

Publication number
MX336145B
MX336145B MX2012010249A MX2012010249A MX336145B MX 336145 B MX336145 B MX 336145B MX 2012010249 A MX2012010249 A MX 2012010249A MX 2012010249 A MX2012010249 A MX 2012010249A MX 336145 B MX336145 B MX 336145B
Authority
MX
Mexico
Prior art keywords
heart failure
chronic heart
treating chronic
methods
relaxin
Prior art date
Application number
MX2012010249A
Other languages
English (en)
Inventor
Dennis R Stewart
Elaine Unemori
Sam L Teichman
Martha Jo Whitehouse
Thomas Dschietzig
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of MX336145B publication Critical patent/MX336145B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de los sujetos humanos que padecen insuficiencia cardiaca crónica. Los métodos descritos en la presente emplean la administración de relaxina. Una relaxina humana H2 farmacéuticamente activa para usarse en el tratamiento de insuficiencia cardiaca crónica en donde la relaxina está adaptada para ser administrable a un sujeto que tiene insuficiencia cardiaca clase II o clase III de acuerdo con la clasificación de la Asociación Cardiaca de Nueva York de insuficiencia cardiaca, al inicio de la administración a una cantidad terapéuticamente efectiva para reducir la frecuencia o duración de la hospitalización del sujeto, comparado a un tratamiento sin dicha relaxina, donde la frecuencia de descompensaciones es reducida a comparación de un tratamiento sin relaxina, y en donde dicha relaxina está formulada por una dosis fija de 10 a 960 µg/kg/día.
MX2012010249A 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica. MX336145B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
PCT/US2009/044247 WO2009140657A2 (en) 2008-05-16 2009-05-15 Method of treating chronic heart failure

Publications (1)

Publication Number Publication Date
MX336145B true MX336145B (es) 2016-01-08

Family

ID=41319370

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010012502A MX2010012502A (es) 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica.
MX2012010249A MX336145B (es) 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010012502A MX2010012502A (es) 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica.

Country Status (10)

Country Link
US (3) US20110144019A1 (es)
EP (2) EP3150219A1 (es)
JP (3) JP2011520917A (es)
CN (2) CN102026649A (es)
AU (1) AU2009246112B2 (es)
BR (1) BRPI0912559A2 (es)
CA (1) CA2724535A1 (es)
MX (2) MX2010012502A (es)
RU (1) RU2512933C2 (es)
WO (1) WO2009140657A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598709A (en) 2008-05-16 2013-09-27 Corthera Inc Treating acute decompensated heart failure with relaxin
JP5970380B2 (ja) 2010-03-10 2016-08-17 ザ ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド リラキシンによるアクアポリンの調節
EP2646572B1 (en) * 2010-12-01 2017-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of chronic heart failure
BR112014000474A2 (pt) * 2011-07-08 2017-02-21 Bayer Ip Gmbh proteínas de fusão libertadoras de relaxina e suas utilizações
CN103764674A (zh) * 2011-08-04 2014-04-30 法瑞斯生物技术有限公司 制备人松弛素-2的方法
WO2013033324A2 (en) 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
EP2795338A4 (en) * 2011-12-21 2015-11-04 Nuclea Biotechnologies Inc BIOMARKERS OF CONGESTIVE HEART FAILURE
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
WO2014115033A2 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
WO2015067113A1 (zh) * 2013-11-07 2015-05-14 上海恒瑞医药有限公司 人松驰素类似物、其药物组合物及其在医药上的应用
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
EP4058048A1 (en) * 2019-11-16 2022-09-21 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Medical composition for treating cardiac wasting and cachexia
CN116406297A (zh) * 2020-08-05 2023-07-07 阿斯克肋匹奥生物制药公司 治疗心脏疾患和充血性心力衰竭以及施用aav载体的方法
RU2748529C1 (ru) * 2020-09-01 2021-05-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения этиологии хронической сердечной недостаточности
WO2024121362A1 (en) * 2022-12-09 2024-06-13 Astrazeneca Ab Dosing regimens using heterodimeric relaxin fusions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE69432704T2 (de) 1993-06-21 2004-02-26 Genentech, Inc., South San Francisco Verfahren zur Herstellung von humanen Relaxin
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
RU2213559C2 (ru) * 2000-01-26 2003-10-10 Тюменская государственная медицинская академия Способ лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
US8492329B2 (en) 2007-07-12 2013-07-23 Compugen Ltd. Bioactive peptides and methods of using same
NZ598709A (en) * 2008-05-16 2013-09-27 Corthera Inc Treating acute decompensated heart failure with relaxin

Also Published As

Publication number Publication date
JP2014237648A (ja) 2014-12-18
CN102026649A (zh) 2011-04-20
EP3150219A1 (en) 2017-04-05
WO2009140657A3 (en) 2010-01-07
US20110144019A1 (en) 2011-06-16
CA2724535A1 (en) 2009-11-19
CN104815319A (zh) 2015-08-05
US20160287672A1 (en) 2016-10-06
BRPI0912559A2 (pt) 2015-10-13
AU2009246112B2 (en) 2013-05-02
JP2017061453A (ja) 2017-03-30
AU2009246112A1 (en) 2009-11-19
US20140005112A1 (en) 2014-01-02
JP2011520917A (ja) 2011-07-21
RU2010151470A (ru) 2012-06-27
MX2010012502A (es) 2011-04-11
RU2512933C2 (ru) 2014-04-10
EP2288366A2 (en) 2011-03-02
EP2288366A4 (en) 2012-05-02
WO2009140657A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
UA99953C2 (uk) Лікування релаксином задишки, асоційованої з гострою серцевою недостатністю
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
BR112014003117A2 (pt) inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
EA201390530A1 (ru) Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
GB0806047D0 (en) Treatment of heart failure
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
WO2011070358A3 (en) Systemic administration of an agent that permeabilises tumour vasculature
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
UA93416C2 (ru) Способ оценки симптомов преждевременной эякуляции
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
UA56675U (ru) Способ местного лечения генерализованного пародонтита c использованием синглетно-кислородной терапии
RU2007140029A (ru) Способ лечения хронической сердечной недостаточности
UA53527U (ru) Способ комплексного лечения хронической сердечной недостаточности у больных пожилого возраста с ишемической болезнью сердца
UA41106U (ru) Способ лечения гипостатической пневмонии у больных с хронической сердечной недостаточностью